Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
February 2022: Study investigates the effectiveness of primary dose CoronaVac COVID-19 vaccines and Pfizer BioNTech booster vaccines in 14 million people in Brazil
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
Cerqueira-Silva, T; Srinivasa, V.K; de Araujo Oliveria, V; Flores-Ortiz, R; et.al.
Nature Medicine
Published online on: 9 February 2022
Available online at: https://doi.org/10.1038/s41591-022-01701-w